r2r01
Small moleculeexperimental
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Jun 30, 2023 (NCT05875948)
Timeline
2020s
- Jan 1, 2023
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
- Relaxin receptor 1AGONIST
RXFP1 agonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06264310 | Phase 2 | Mar 1, 2024 | River 3 Renal Corp. |
| NCT05875948 | Phase 2 | Jun 30, 2023 | River 3 Renal Corp. |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| River 3 Renal Corp. | For profit | 2 | 2 | 1 | 2023 |
1 organizations
Page 1 / 1